{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:43:12Z","timestamp":1792798992679,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA101642"],"award-info":[{"award-number":["CA101642"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","award":["CA209-9C7"],"award-info":[{"award-number":["CA209-9C7"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.medj.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T10:38:47Z","timestamp":1710153527000},"page":"311-320.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis"],"prefix":"10.1016","volume":"5","author":[{"given":"Anne","family":"Knisely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schmeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolyn S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul A.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.02.003_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.02.003_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.02.003_bib3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib6","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib7","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib8","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer:\u00a0Results From the KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib9","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.02.003_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The Unique Molecular and Cellular Microenvironment of Ovarian Cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s12094-012-0888-x","article-title":"Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model","volume":"14","author":"Passot","year":"2012","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1158\/0008-5472.CAN-15-1620","article-title":"Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer","volume":"76","author":"Winner","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.02.003_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.2010.03635.x","article-title":"Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients","volume":"69","author":"Ruf","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2024.02.003_bib18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.1991.9.12.2095","article-title":"Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer","volume":"9","author":"Pai","year":"1991","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-9966-28-18","article-title":"Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis","volume":"28","author":"Str\u00f6hlein","year":"2009","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.02.003_bib20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2024.02.003_bib21","first-page":"833","article-title":"A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer","volume":"18","author":"Bokemeyer","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.medj.2024.02.003_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1479-5876-5-66","article-title":"Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease\u00a0<\u00a01\u00a0cm) associated with ovarian cancer or primary peritoneal carcinoma","volume":"5","author":"Lenzi","year":"2007","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.medj.2024.02.003_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2012.228","article-title":"Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation","volume":"21","author":"Gujar","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2024.02.003_bib24","first-page":"4272","article-title":"The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites","volume":"7","author":"Ai","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.medj.2024.02.003_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clim.2009.08.007","article-title":"Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival","volume":"133","author":"Dobrzanski","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.medj.2024.02.003_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.medj.2024.02.003_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2016.49","article-title":"Intraperitoneal immunotherapy: historical perspectives and modern therapy","volume":"23","author":"Morano","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.medj.2024.02.003_bib28","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T\u00a0cells eradicate ovarian tumors in\u00a0vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2024.02.003_bib29","article-title":"L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice","volume":"11","author":"Hong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2024.02.003_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.medj.2024.02.003_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ijgc-2021-002492","article-title":"Advances in immunotherapy for cervical cancer: recent developments and future directions","volume":"32","author":"Sherer","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.medj.2024.02.003_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12885-022-09210-2","article-title":"Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer","volume":"22","author":"Nyein","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medj.2024.02.003_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib34","first-page":"459","article-title":"Chemotherapy in endometrial cancer","volume":"4","author":"Obel","year":"2006","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.02.003_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.medj.2024.02.003_bib37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.02.003_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2024.02.003_bib39","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:33:51Z","timestamp":1772919231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2666634024000758"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.02.003","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}